WIPO logo
Мобильная версия | Deutsch | English | Español | Français | 日本語 | 한국어 | Português | 中文 | العربية |
PATENTSCOPE

Поиск по международным и национальным патентным фондам
World Intellectual Property Organization
Поиск
 
Просмотреть
 
Перевод
 
Настройки
 
Новости
 
Войти в систему
 
Помощь
 
maximize
Автоматизированный перевод
1. (WO2007063509) PHOSPHOCREATINE COMPLEXES
Примечание: Текст, основанный на автоматизированных процессах оптического распознавания знаков. Для юридических целей просьба использовать вариант в формате PDF

CLAIMS

1. A phosphocreatine complex having the general formula:


wherein M is a pharmaceutically acceptable metal and An" is an organic or inorganic anion, and pharmaceutically acceptable salts thereof.

2. The phosphocreatine complex according to claim I7 wherein M is a metal selected from the group consisting of Magnesium (Mg) , Calcium (Ca) , Cobalt (Co) , Manganese (Mn) , Zinc (Zn) , Cadmium (Cd) , Copper (Cu) , Barium (Ba) , Strontium (Sr) and Iron (Fe) .

3. The phosphocreatine complex according to claim 1 or 2 , wherein the anion is selected from the group consisting of acetate, butirrate, propionate, and the anions provided with free radical scavenger neutralizing activity.

4. The phosphocreatine complex according to claim 3 , wherein said anions provided with free radical scavenger neutralizing activity are selected from the group consisting of ascorbate, benzoate, sulfonium and di-sulfonium anions.

5. The phosphocreatine complex according to any of claims 1 to 4, wherein said pharmaceutically acceptable salt is selected from the group consisting of sodium salt, potessium salt, ammonium salt, lithium salt, choline salt, silver salt.

6. The phosphocreatine complex according to any of claims 1 to 5, of formula:


wherein An" is as defined in claim 3 or 4.

7. The phosphocreatine complex according to any of claims 1 to 6 , as a medicament .

8. A pharmaceutical composition comprising at least a phosphocreatine complex according to any of claims 1 to 6 and a pharmaceutically acceptable carrier and/or diluent.

9. Use of a phosphocreatine complex according to any of claims 1 to 6 for preparing a medicament for the treatment of central nervous system diseases .

10. Use according to claim 9, wherein said central nervous system diseases are selected from the group consisting of diseases of the central nervous system which imply energy deficiency, diseases of the central nervous system which imply deficiency of creatine and diseases of the central nervous system which imply deficiency of the creatine transporter.

11. Use according to claim 9, wherein said central nervous system diseases are selected from the group consisting of hereditary deficiency of the creatine transporter, hereditary deficiency of the Guanidinoacetate-methyltransferase (GAMT) enzymes, hereditary deficiency of the Arginine-glycine-amidinotransferase (AGAT) enzymes, brain stroke, ischemic stroke, mitochondrial encephalopathies, Lateral Amiothrophic Sclerosis, Alzheimer disease, Parkinson disease, Huntington's Chorea, anoxic .encephalopathy of the new born.